SMMT:NSD-Summit Therapeutics PLC (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 20.46

Change

+1.66 (+8.83)%

Market Cap

USD 14.57B

Volume

2.41M

Analyst Target

USD 4.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. Its lead development candidate, ivonescimab, is a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and is also in Phase III clinical trials for the treatment of non-small lung cancer. The company has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. Summit Therapeutics Inc. was founded in 2003 and is headquartered in Miami, Florida.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.25 (-0.26%)

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

+8.60 (+1.39%)

USD 69.68B
ARGX argenx NV ADR

+16.53 (+2.91%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

+11.07 (+4.33%)

USD 31.94B
ONC BeiGene, Ltd.

+3.74 (+1.38%)

USD 28.70B
RPRX Royalty Pharma Plc

+0.11 (+0.35%)

USD 19.31B
UTHR United Therapeutics Corporatio..

+5.38 (+1.75%)

USD 14.37B
INCY Incyte Corporation

+1.42 (+2.33%)

USD 14.22B
MRNA Moderna Inc

+0.56 (+2.06%)

USD 13.74B
INSM Insmed Inc

+1.44 (+2.00%)

USD 13.70B

ETFs Containing SMMT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.65% 87% B+ 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.65% 87% B+ 89% A-
Trailing 12 Months  
Capital Gain 417.97% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 417.97% 99% N/A 99% N/A
Trailing 5 Years  
Capital Gain 785.71% 98% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 785.71% 98% N/A 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 143.57% 87% B+ 94% A
Dividend Return 143.57% 87% B+ 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 281.84% 19% F 9% A-
Risk Adjusted Return 50.94% 94% A 78% C+
Market Capitalization 14.57B 99% N/A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector